EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association between antibiotic use, immune-related adverse events, and efficacy of immunotherapy in esophageal squamous cell carcinoma

Tomoaki Shirakawa, Hiroo Imai, Ken Saijo, Ryo Saito, Shiori Ishikawa, Iori Takahashi, Keigo Komine, Kota Ouchi, Yuki Kasahara, Sakura Taniguchi, Yuya Yoshida, Ryunosuke Numakura und 4 weitere

International Journal of Clinical Oncology · 2026

DOI: 10.1007/s10147-026-03036-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2026. Verfasst von Tomoaki Shirakawa und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Seiryo-machi 4-1, Aobaku, Sendai, 980-8575, Japan. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immune checkpoint inhibitors (ICIs) are essential for treating esophageal squamous cell carcinoma (ESCC). As antibiotics (Abx) may reduce ICI efficacy, and immune-related adverse events (irAEs) relate to better outcomes, we investigated their association. Patients and methods We retrospectively analyzed 121 advanced or metastatic ESCC patients treated with ICIs, assessing outcomes based on Abx use and irAEs.

Results

Forty-one patients (33.9%) were in the Abx (+) group, showing a significantly shorter median progression-free survival (PFS) (2.5 vs. 6.5 months; p = 0.029) and lower disease control rate (36.8% vs. 60.9%; p = 0.0145) than those in the Abx (−) group. irAEs were less frequent in the Abx (+) group (29.3% vs. 58.8%; p = 0.0037). The positive impact of irAEs on ICI efficacy was significant in overall population [irAE(−) vs. irAE(+): PFS, 4.4 months (95% CI 2.5–5.3) vs. 8.8 months (95% CI 5.9–13.7); log-rank p = 0.001; Hazard ratio (HR) 1.76, 95% CI 1.14–2.74; p = 0.011; overall survival (OS), 10.6 months (95% CI 7.0–13.1) vs. 18.1 months (95% CI 9.2–25.9); log-rank p = 0.043; HR 1.61, 95% CI 1.01–2.55; p = 0.046] but diminished if received Abx. Notably, the Abx (−)/irAE (+) group had the best outcomes, while the Abx (+)/irAE (−) group had the worst PFS (8.7 vs. 2.4 months; HR 2.07; p = 0.011) and OS (18.1 and 6.8 months; HR 1.89; p = 0.036).

Conclusion

Antibiotic use was linked to reduced ICI efficacy and fewer irAEs, suggesting impaired immune activation in ESCC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsEsophageal Squamous Cell CarcinomaEsophageal NeoplasmsImmune Checkpoint InhibitorsImmunotherapyHumansFemaleMaleAgedRetrospective StudiesMiddle AgedAged, 80 and overProgression-Free SurvivalAdult

Stichwörter der Autor:innen

AntibioticsEsophageal squamous cell carcinomaImmune checkpoint inhibitorImmune-related adverse events

Substanzen

Anti-Bacterial AgentsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Seiryo-machi 4-1, Aobaku, Sendai, 980-8575, Japan.
  • Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Seiryo-machi 4-1, Aobaku, Sendai, 980-8575, Japan. hiroo.imai.d8@tohoku.ac.jp.
  • Department of Medical Oncology, Tohoku University Hospital, Seiryo-machi 4-1, Aobaku, Sendai, 980-8575, Japan. hiroo.imai.d8@tohoku.ac.jp.
  • Department of Medical Oncology, Tohoku University Hospital, Seiryo-machi 4-1, Aobaku, Sendai, 980-8575, Japan.

Zitieren

APA

Shirakawa, T., Imai, H., Saijo, K., Saito, R., Ishikawa, S., Takahashi, I., Komine, K., Ouchi, K., Kasahara, Y., Taniguchi, S., Yoshida, Y., Numakura, R., Wakayama, S., Shirota, H., Takahashi, M., & Kawakami, H. (2026). Association between antibiotic use, immune-related adverse events, and efficacy of immunotherapy in esophageal squamous cell carcinoma. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-026-03036-9

Vancouver

Shirakawa T, Imai H, Saijo K, Saito R, Ishikawa S, Takahashi I, et al. Association between antibiotic use, immune-related adverse events, and efficacy of immunotherapy in esophageal squamous cell carcinoma. International Journal of Clinical Oncology. 2026. doi:10.1007/s10147-026-03036-9

BibTeX
@article{Shirakawa2026,
  author = {Shirakawa, Tomoaki and Imai, Hiroo and Saijo, Ken and Saito, Ryo and Ishikawa, Shiori and Takahashi, Iori and Komine, Keigo and Ouchi, Kota and Kasahara, Yuki and Taniguchi, Sakura and Yoshida, Yuya and Numakura, Ryunosuke and Wakayama, Shonosuke and Shirota, Hidekazu and Takahashi, Masanobu and Kawakami, Hisato},
  title = {Association between antibiotic use, immune-related adverse events, and efficacy of immunotherapy in esophageal squamous cell carcinoma},
  journal = {International Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1007/s10147-026-03036-9}
}
Kostenlos starten →